Literature DB >> 19351277

Treatment strategies for cancer patients with breakthrough pain.

Alessandra Casuccio1, Sebastiano Mercadante, Fabio Fulfaro.   

Abstract

BACKGROUND: Breakthrough pain (BTP) is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. It is normally severe in intensity, has a rapid onset, has a variable duration (on average 30 min) and is considered a negative prognostic factor.
OBJECTIVE: To verify the data in the literature about therapy strategies for BTP in cancer patients.
METHODS: To find clinical trials investigating drug therapy for BTP.
CONCLUSION: The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset. Fentanyl delivered by recently developed systems seems to be the best option to cover the temporal pattern of BTP, although the treatment should be highly personalized to provide the best in individuals, balancing patients' preferences and clinical needs. The doses to be administered is still a matter of controversy in the literature; additional studies with specific designs should be conducted to settle the question.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351277     DOI: 10.1517/14656560902851510

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  [Questions from a pain physician reader: Evidence, empiricism, eminence - all the same?].

Authors:  W Meißner; F Petzke; R Sabatowski
Journal:  Schmerz       Date:  2013-08       Impact factor: 1.107

2.  Time to pain relief after immediate-release morphine in episodic pain: the TIME study.

Authors:  Claudio Lo Presti; Alessandro Roscetti; Davide Muriess; Massimo Mammucari
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.